

Release of Securities from ASX Escrow Restriction

Medical technology company, **HeraMED Limited (ASX:HMD)** (“HeraMED” or the “Company”) advises in accordance with ASX Listing Rule 3.10A that the securities referred to below will be released from ASX escrow on or after their respective escrow expiry date, as referred to below.

Securities	Number	Escrow Expiry Date
Unlisted options expiring 5/12/21 @ \$0.25	4,578,000	5 December 2019

Further, the Company advises that the following securities will be released from ASX escrow on or after their respective escrow expiry date as referred to below **but they will be subject to escrow for an Additional Period of one year** ending on 5 December 2020 despite the escrow period imposed by the ASX on those securities having expired on 5 December 2019.

Securities	Number	Escrow Expiry Date
Ordinary Fully Paid Shares	8,277,494	5 December 2019
Unlisted options expiring 5/12/21 @ \$0.00002	2,743,655	5 December 2019

These escrow arrangements and option terms were fully disclosed in:

- Section 8.2 of the Company’s original prospectus dated 15 October, 2018 (**Original Prospectus**) that set out the terms of issue of the New Options;
- Section 3.11 of the Supplementary Prospectus dated 23 November, 2018 (**Supplementary Prospectus**) that had the effect of inserting Section 7.14 (as therein quoted) into the Original Prospectus;
- Section 3.12 of the Supplementary Prospectus that set out the terms of issue of the Vendor Options and had the effect of inserting Section 8.2A (as therein quoted) into the Original Prospectus; and
- ASX Announcement of 10 December 2018 titled “Voluntary Escrow”.

-ENDS-

HeraMED Limited

CEO and Co-Founder

David Groberman

M:+972-52-6991188

E: David@hera-med.com

Company Secretary

Stephen Buckley

T: +61 (0)8 6189 1155

E: stephen@companysecsol.com.au

For personal use only

About HeraMED Limited (ASX:HMD):

HeraMED Limited is an innovative medical technology company delivering smart pregnancy monitoring solutions for home and professional use. HeraMED provides peace of mind to expecting parents by solving problems associated with the reliability of pre-natal analysis, as well as the cost and shortage in fundamental services through end-to-end medical grade solutions utilising monitoring devices, cloud based platforms and AI capabilities.

HeraMED is commercialising the worlds most advanced, smart medical grade ultrasound monitoring device HeraBEAT. The device has passed multiple clinical trials and secured approval by key regulatory bodies including TGA (Australia), CE (Europe) and AMAR (Israel) for commercial sale.

The Company has partnerships with two leading medical organisations, the Mayo Clinic and TEVA Pharmaceutical Industries Inc. (NYSE: TEVA). HeraMED diversifying its product range and services with the launch of SaaS services and cloud based monitoring systems.

For personal use only